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EXTRACELLULAR AND 
STANDARD UNIVERSITY OF 
WISCONSIN SOLUTIONS 
PROVIDE EQUIVALENT 
PRESERVATION OF 
MYOCARDIAL FUNCTION 
The deleterious etfect of hyperkalemic ardioplegic solutions on coronary 
endothelium has been documented and has also been demonstrated with 
University of Wisconsin solution. We evaluated a new extracellular Univer- 
sity of Wisconsin formulation for etficacy in heart preservation. Six 
neonatal piglet hearts were arrested with and stored in the standard 
intracellular University of Wisconsin solution (group 1: K + 125 mEq/L, 
Na + 29 mEq/L). Six piglet hearts were preserved for 24 hours with an 
extracellular University of Wisconsin solution that differed only in the 
concentrations of potassium and sodium (group 2: K + 25 mEq/L, Na + 129 
mEq/L). Hearts underwent modified reperfusion with leukocyte-depleted 
aspartate-glutamate enriched blood cardioplegic solution followed by con- 
version to a left-sided working mode on a Langendortf circuit with 
perfusion from a support pig. Stroke work index was calculated at left 
ventricular end-diastolic pressures of 3, 6, 9, and 12 mm Hg. Sixty minutes 
after reperfusion, there was no significant ditference in stroke work index 
between group 1 (16.4 -- 1.9 x 1000 erg/gm) and group 2 (15.3 -- 2.7 x 1000 
erg/gm). There was also no significant ditference in high-energy phosphate 
stores or myocardial water content between the two groups. Extracellular 
University of Wisconsin solution provides myocardial preservation equiv- 
alent to standard University of Wisconsin solution while preventing expo- 
sure of coronary endothelium to high ievels of potassium, which justifies its 
use in clinical heart transplantation. (J TrIORAC CARDIOVASC SURG 1995; 
110:738-45) 
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T he extension of acceptable ischemic time in heart transplantation with improved myocardial pres- 
ervation techniques has expanded the donor pool 
and may facilitate the future use of HLA matching. 1 
The University of Wisconsin (UW) solution has 
become recognized as the "gold standard" for kid- 
ney and liver preservation, providing superior re- 
sults in both laboratory and clinical studies. 2-4 The 
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UW solution contains macromolecular impermeant 
molecules to prevent cell swelling, a buffer to pre- 
vent intracellular acidosis, a colloid to facilitate 
vascular flushout, and several additional compo- 
nents theoretically important in organ preservation. 
In addition, the solution has a high potassium 
concentration (125 mEq/L) to approximate the in- 
tracellular environment and theoretically prevent 
Na-K adenosinetriphosphatase (ATPase) activity 
and its resultant cellular accumulation of water and 
depletion of adenosine triphosphate (ATP) stores. 5
Encouraging laboratory results that showed com- 
plete functional recovery in hearts preserved with 
UW solution for as long as 24 hours 6-s prompted 
interest in the use of UW for clinical heart preser- 
vation. In our laboratory, hearts preserved with UW 
for 12 hours demonstrated functional recovery of 
100% of nonischemic control hearts, compared with 
33% for hearts preserved with Stanford cardioplegic 
solution. 9 A randomized clinical trial that compared 
UW and Stanford solution for heart preservation at 
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our institution resulted in our adoption of UW for 
heart presep¢ation i late 1990. l° 
Concern has been expressed about the high po- 
tassium concentration of UW solution with respect 
to its possible deleterious effects on coronary endo- 
thelium. The damaging effects of hyperkalemic car- 
dioplegic solutions are documented lm3 and these 
effects have recently been associated with UW solu- 
tion. 14 In our laboratory, we have demonstrated that 
multidose UW solution produces a near-complete 
loss of endothelium-dependent vasodilatation and 
nitric oxide releaseJ 5
Implications of endothelial dysfunction include 
impaired autoregulation of myocardial perfusion 16 
and increased propensity toward thrombosis 17 and 
atherosclerosisJS, 19 We recently conducted a retro- 
spective study that compared the prevalence of 
cardiac allograft vasculopathy (CAV) in the final 
100 recipients in our program to have the donor 
hearts preserved with Stanford cardioplegia (potas- 
sium 30 mEq/L) with the prevalence in the first 100 
recipients to have the donor hearts preserved with 
UW solution. The prevalence of cardiac allograft 
vasculopathy at 24 months of follow-up was 21% in 
the UW group compared with 10.5% in the Stanford 
group. 2° Preservation solution was the only signifi- 
cant (p = 0.001) factor influencing the prevalence of 
cardiac allograft vasculopathy. 
On the basis of this finding, we sought a heart 
preservation solution that would provide the same 
excellent myocardial preservation as standard UW 
solution and provide improved endothelial preser- 
vation. We hypothesized that reducing the potas- 
sium concentration to 25 mEq/L and raising the 
sodium qoneentration by an equal amount would 
not induce the endothelial dysfunction caused by 
standard UW solution and would simultaneously 
maintain excellent preservation of myoeardial func- 
tion. 
Methods 
Experimental design. Two groups were evaluated. The 
first group (n = 6) served as a control group and included 
piglet hearts that were arrested with and stored in stan- 
dard high-potassium (125 mEq/L) UW solution. The 
experimental group (n = 6) was used to evaluate the use 
of a low-p0tassium (25 mEq/L) UW formulation for arrest 
and storage. The final composition of each solution is 
listed in Table I. To ensure uniformity of the other 
components between groups, a single stock solution was 
made in our laboratoly to which potassium and sodium 
were added to produce the final forlnulations. All person- 
nel performing the arrest and reperfusion procedures 
Table I. Composition of the preservation solutions 
Solution 
Extracellular UW Intracellular UW 
Component (low K) (high K) 
Pentafraction (%) 5 5 
Lactobionate 100 100 
(mmol/L) 
Raffinose (mmol/L) 30 30 
Adenosine (mmol/L) 5 5 
MgSO4 (mmol/L) 5 5 
Glutathione (mmol/L) 3 3 
Allopurinol (mmol/L) 1 1 
KH2PO 4 (mmol/L) 25 25 
NaOH (mmol/L) 129 29 
KOH (mmol/L) - -  104 
Osmolarity (mmol/L) 300-320 300 
pH 7.6-7.8* 7.6-7.8 
Pentafraction was a generous gift from DuPont Pharmaceuticals, Wilm- 
ington, Del. 
*pH of extracellular (low-potassium) solution adjusted with the addition of 
hydrochloric a id. 
were blinded as to which UW formulation was being used 
for arrest and storage. 
Arrest. Our methods of neonatal piglet heart arrest, 
storage, and reperfusion have previously been described 
and were used in this study. 8' 9 All animals received 
humane care in compliance with the "Principles of Lab- 
oratory Animal Care" formulated by the National Society 
for Medical Research and the "Guide for the Care and 
Use of Laboratoly Animals" prepared by the Institute of 
Laboratory Animal Resources and published by the Na- 
tional Institutes of Health (NIH Publication No. 86-23, 
revised 1985). Neonatal Duroc piglets (24 to 72 hours old) 
were anesthetized and the lungs mechanically ventilated 
with an inspired oxygen fraction of 1.0 at a rate of 15 to 20 
cycles/min. The heart and great vessels were exposed, and 
the hemiazygous vein and left subclavian artery were 
ligated. After heparin (1000 units) and cefazolin sodium 
(100 mg) were injected into the main pulmonary artery, 
the innominate artery was cannulated and connected to a 
pressure monitor. Arrest was initiated with ligation of the 
superior and inferior vena cavae, crossclamping of the 
descending thoracic aorta, and infusion of high- or low- 
potassium UW solution at 4 ° C into the aortic root via the 
innominate artery cannula. Simultaneously with the infu- 
sion of UW, the left pulmonary veins and the main 
pulmonary artery were incised to decompress the heart. 
The cardioplegic solution was infused for 2 minutes at a 
pressure of 40 to 50 mm Hg with concurrent opical 
cooling. 
Storage. Cardiectomy was done by division of the vena 
cavae, pulmonary veins, aorta, and pulmonary artery. 
Immediately after excision the hearts were immersed in 
the same solution used for arrest at a temperature of 4 ° C. 
The innominate artery cannula was left in place during 
storage. Each container was sealed and packed in ice, and 
a temperature of 0.5 ° to 1 ° C was maintained for 24 hours. 
Reperfusion. Reperfusion was achieved with use of an 
isolated blood-perfused working left-sided heart model, 
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Fig. 1. Diagram of isolated perfusion circuit. Blood from support animal can be pumped to either aortic 
root or to adjustable-height reservoir that supplies left atrium. Afterload is determined by adjustable-height 
aortic column. Cardiac output can be measured by collecting coronary sinus etttuent via pulmonary artery 
cannula plus overflow from aortic column. A, Femoral artery; V,, femoral vein; LA, left atrium; LV, left 
ventricle; RA, right atrium; RV, right ventricle; PA, pulmonary artery; Ao, aorta; HR, heated reservoir 
containing blood cardioplegia (see text). 
which is illustrated in Fig. 1. This model allows perfusion 
both via the innominate artery in the nonworking mode 
and via the left atrium when converted to the working 
mode. 
Adolescent (4 to 6 months old, 60 to 70 kg) Duroc 
support pigs used for reperfusion were anesthetized and 
the lungs ventilated with 100% oxygen. Arterial blood gas 
values were obtained every 20 minutes, and appropriate 
ventilator adjustments or correction of metabolic acidosis 
with sodium bicarbonate, or both, were done. After 
cannulation of the right femoral artery and vein, antico- 
agulation was achieved by infusion of 40,000 units heparin 
and was maintained with the addition of 10,000 units/hr. 
Blood from the support animal was directed through a 
roller pump to a heated reservoir and bubble trap (model 
BCD Advanced, Shiley Inc., Irvine, Calif.) and to a heated 
height-adjustable reservoir. Reperfusion and suspension 
of the heart was achieved by connection of the innominate 
artery cannula to the heated reservoir and bubble trap 
while distal aortic crossclamping was maintained. For the 
first 10 minutes the reperfusate was modified by the 
addition of aspartate-glutamate enriched cardioplegic so- 
lution and by leukocyte depletion. Whole blood and 
aspartate-glutamate enriched cardioplegic solution were 
delivered to the roller pump in a 4:1 ratio and mixed 
immediately after the pump. Leukocyte depletion was 
accomplished by directing the enriched blood through two 
filters (model RC100, Pall Filter Corp., Glen Cove, N.Y.) 
placed in parallel between the roller pump and the heated 
reservoir and bubble trap. The blood fiow was diverted to 
a new pair of leukocyte filters after 5 minutes of reperfu- 
sion to ensure complete depletion. After 10 minutes of 
reperfusion, aspartate-glutamate cardioplegic solution de- 
livery and leukocyte depletion were terminated. Blood 
samples were drawn from the support pig arterial cannula 
just before reperfusion and from the innominate artery 
cannula fter 2 and 8 minutes of reperfusion to determine 
the degree of leukocyte depletion. 
Modified reperfusion was begun via the innominate 
artery cannula at 50 mm Hg and 37°C for 10 minutes, 
followed by 10 minutes of whole blood reperfusion at 80 
mm Hg before couversion to the working mode. The aorta 
was cannulated with a 16-gauge perfusion cannula after 
modified reperfusion was terminated and connected to an 
open adjustable column. Blood from the pulmonary artery 
was collected to reßect coronary sinus etfluent. Blood 
from the aortic column and pulmonary artery was filtered 
and returned to the support animal. 
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Fig. 2. No significant difference in SWI was noted between extracellular UW and intracellular UW 
s01utions at each level of LVEDP. LA, Left atrial pressure (mm Hg). 
To convert hearts to working mode perfusion, the left 
atrium was opened between the right and left pulmonary 
veins, and the septum was inspected for the presence of a 
patent foramen ovale. If present it was closed with the use 
of 5-0 polypropylene suture. A purse-string pledget-sup- 
ported 4-0 polypropylene suture was placed around the 
left atriotomy, which was then cannulated and connected 
to a height-adjustable 37 °C water-jacketed reservoir. The 
reservoir was supplied with arterial blood from a second 
roller pump. 
Fiberoptic transducer-tipped catheters (1.3 mm outer 
diameter; model 100-4, Camino Laboratories, San Diego, 
Calif.) were advanced into the left atrium and the left 
ventricle for pressure monitoring and recording. 
Evaluation of functional recovery. After 20 minutes of 
innominate artery perfusion and 30 minutes of working- 
mode perfusion, left ventricular functional assessment was 
made. Function curves were determined by measurement 
of cardiac output (sum of aortic column overflow and right 
ventricular return) at a constant aortic pressure of 80 mm 
Hg and at left ventricular end-diastolic pressures 
(LVEDPs) of 3, 6, 9, and 12 mm Hg. The stroke work 
index (SWI; ergs per gram) was calculated from the 
following equation: 
(MAP - LVEDP) × CO 
SWI = × 1333 
HR × WT 
where MAP is mean aortic pressure (80 mm Hg), CO is 
cardiac output (milliliters per minute), HR is heart rate 
(beats per minute), and WT is weight (grams). Functional 
assessment was done at 30, 60, 90, and 120 minutes after 
initiation of working-mode perfusion. 
Myocardial high-energy phosphate assessment. After 
functional determinations were completed, transmural 
biopsy samples of the left ventricular free wall were 
obtained and rapidly frozen in liquid nitrogen. Measure- 
ments for ATP, adenosine diphosphate (ADP), adenosine 
monophosphate (AMP), and cr•atinine phosphate were 
made with the use of high-pressure liquid chromatogra- 
phy. 
Ultrastruetural assessment. Transmural left ventricu- 
lar biopsy specimens were taken at the completion of the 
functional assessment and fixed in 2.5% glutaraldehyde. 
One-micron sections were stained with uranyl acetate and 
lead citrate and examined on a Zeiss EM 109 microscope 
(Zeiss, Munich, Germany). Ultrastructural changes were 
evaluated in a blinded fashion. 
Myoeardial water eontent. Left ventricular biopsy spec- 
imens were weighed before and after desiecation at 100 ° C 
for 24 hours. The myocardial water content was calculated 
from the wet and dry weights. 
Results 
Functional recovery. Function curves are dia- 
grammed in Fig. 2. Comparisons of SWI between 
groups were made at an LVEDP of 9 mm Hg, which 
corresponded to the peak of the Starling curve. 
Comparison between groups was made with func- 
tional data obtained 60 minutes after initiation of 
working-mode perfusion. The mean function of the 
hearts that received low-potassium UW (SWI 
15.3 _+ 2.7 × 10E3 erg/gin) was not different from 
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Fig. 3. No significant difference between extracellular 
UW and intracellular UW solutions was noted for high- 
energy phosphates ATP, ADP, AMP, and creatine phos- 
phate (CP). 
that of the control (high-potassium UW) hearts 
(SWI 16.4 _+ 1.9 × 10E3 erg/gm). 
High-energy phosphates. High-energy phosphate 
levels are shown in Fig. 3. ATP, ADP, AMP, and 
creatinine phosphate levels were similar in both 
groups. 
Ul t ras t ruc ture .  Electron micrographs of biopsy 
specimens obtained after functional assessment 
demonstrated similar findings in both groups. All 
hearts howed mild myofibrillar crowding and mild 
interstitial edema. In addition, there was mild mito- 
chondrial enlargement and minimal nuclear chro- 
matin margination. 
Additional examination of capillary surfaces did 
not reveal major endothelial structural abnormali- 
ties. Some increase in the number of pinocytotic 
vesicles was noted in endothelial cells of both 
groups, but this did not correlate strongly with the 
preservation solution used. 
Myocard ia l  water  content .  Mean watet content 
was similar in the two groups (Fig. 4). 
Discuss ion  
The optimal cardioplegic solution for heart rans- 
plantation must provide excellent myocardial pres- 
ervation for up to 6 to 8 hours after a single adminis- 
tration given to arrest the heart. The duration of 
safe ischemic times allows for the ability to procure 
organs throughout North America. 
Until mid-1990 the method of heart preservation 
used at our institution consisted of arrest with the 
Stanford eardioplegic solution followed by storage 
in cold normal saline solution. The Stanford solu- 
tion ineludes dextrose to provide substrate for the 
ischemic heart, mannitol as an impermeant to pre- 
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Fig. 4. No significant difference inmyocardial water con- 
tent was noted between extracellular UW and intracellu- 
lar UW so|utions. 
vent hypothermia-induced ll swelling, magnesium 
for membrane stabilization, and 30 mEq/L of potas- 
sium to induce rapid cardiac arrest. 21 The Stanford 
solution has provided acceptable myocardial preser- 
vation for short to moderate duration (less than 6 
hours) ischemic times_ 
The UW solution was developed by Wahlberg, 
Southard, and Belzer 22 for pancreas preservation. 
It has provided excellent laboratory 2' 3 and clini- 
cal 4'23 results for kidney and liver transplan- 
tation. Several aboratory studies that evaluated 
UW for heart preservation have shown superior 
myocardial preservation i  comparison with re- 
sults with other cardioplegic solutions. 6-8 These 
results prompted randomized clinical trials, a°' 24 
which led to the adoption of UW solution for 
heart preservation at several centers, including 
our own. 
Because the presence of many of the components 
of UW solution was based on theory, several studies 
have been conducted to determine which compo- 
nents are essential to the solution. 7'25'26 These 
studies have concluded that the impermeants 
lactobionate and raffinose, the colloid hydroxyethyl 
starch (Pentafraction, DuPont Pharmaceuticals, 
Wilmington, Del.), adenosine as substrate for ATP 
production, and the free radical scavenger glutathi- 
one all contribute to the effectiveness of the UW 
solution. 
Most studies that evaluated the UW solution have 
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also concluded that its intracellular composition 
(the high potassium concentration) contributes sig- 
nificantly to the etficacy of preservation. 5' 9, 27 This 
argument isbased largely on findings of early studies 
that used the high-potassium Collins or Sacks solu- 
tions, 28 which resulted in improved functional recov- 
ery in comparison with the recovery when simple 
extracellular solutions were used. 
Previous investigators have evaluated the efficacy 
of an extracellular UW solution. Moen and associ- 
ates 29 demonstrated qual or slightly more effective 
preservation of the canine liver, kidney, and pan- 
creas with an extracellular UW solution. Oka and 
colleagues 3° have shown good lung preservation 
with a low-potassium UW formulation. 
Few groups have evaluated a low-potassium UW 
solution for heart preservation. Howden and asso- 
ciates 31 evaluated an extracellular UW solution (po- 
tassium 35 mEq/L) without hydroxyethyl starch in a 
heterotopic rat heart transplant model and reported 
no difference in survival with the standard UW 
solution. Actual myocardial function could not be 
assessed in this model. Okuchi and associates 32
compared a low-potassium (30 mEq/L) solution 
with the glucose-insulin-potassium and Bret- 
schneider solutions and concluded that the mod- 
ified UW solution was the most effective but made 
no comparison with conventional UW solution. 
Ko and colleagues 27 found no decline in most 
myocardial parameters with the exception of elas- 
tance in canine hearts stored for 6 hours with 
potassium and sodium reduced UW solution as 
compared with controls. We believe our study is 
the first to make a direct functional comparison 
between extracellular and intracellular UW solu- 
tions for heart preservation. 
Our results indicate equivalent functional recov- 
ery with extracellular or intracellular UW solution. 
The only difference between the two solutions in our 
study was the concentrations of potassium and so- 
dium. Support for the belief that the intracellular 
nature of UW solution contributes significantly to its 
protective effect was not demonstrated in this 
experiment. It is argued that an intracellular storage 
solution will[ prevent hypothermia-induced cell 
swelling by preventing flux of sodium and potassium 
across the cell membrane. Anaerobic hypothermia 
suppresses t]he activity of the sodium-potassium 
pump, allowing sodium to enter the cell and induc- 
ing the swelling of the cell by accumulation ofwater. 
We hypothesize that the osmotic force of the im- 
permeants lactobionate, raffinose, and pentastarch 
found in UW prevents the cell swelling seen with 
simpler extracellular preservation solutions and 
eliminates the need for intracellular composition. 
This study was initially prompted by our observa- 
tion of increased cardiac allograft vasculopathy in
patients whose hearts were preserved with UW 
solution. 2° We have not established a causal link 
between hyperkalemic ardioplegic solutions and 
the development of cardiac allograft vasculopathy, 
and our study was retrospective and nonrandom- 
ized. However, the link between hyperkalemic car- 
dioplegic solutions, including UW in particular, 
and endothelial dysfunction has been established. 
Olinger and colleagues 33studied the effect of expo- 
sure of monkey cephalic vein grafts to hyperkalemic 
solution on subsequent cholesterol accumulation. 
That group observed a significant increase in cho- 
lesterol deposition 12 weeks after operation in vein 
grafts filled with hyperkalemic cardioplegic solution 
(potassium 27 mEq/L) for 30 minutes compared 
with that in control grafts filled with normokalemic 
cardioplegic solution. Many recent studies have 
shown structura111'34 and functiona112-15 damage 
after infusion of hyperkalemic ardioplegic solu- 
tions. Hoover and colleagues 11perfused canine jug- 
ular vein grafts with hyperkalemic cardioplegic (po- 
tassium 40 mEq/L) in one half of the vein and with 
lactated Ringer's solution in the other half and 
grafted the vein to the carotid artery. Light micros- 
copy revealed intense adventitial fibrosis and ap- 
pearance of fibroblast-like cells in the outer layer of 
the vein wall in the segment infused with hyperkale- 
mic cardioplegic solution. Mankad, Chester, and 
Yacoub 13 found that raising the concentration of 
potassium in the cardioplegic solution from 20 to 
30 mEq/L produced a significant abolition of 
endothelial response to 5-hydroxytryptamine and 
nitroglycerin-induced vasodilatation. Carticr and 
colleagues 14showed inhibition of endothelium-de- 
pendent coronary artery relaxation in response to 
5-hydroxytryptamine and nitroprusside infusion af- 
ter a single dose of cold UW. Pearl and associates 15
evaluated multidose UW as an alternative to blood 
cardioplegia nd found a similar complete loss of 
response to bradykinin and nitroprusside infusion 
and a loss of endothelial nitric oxide release. We are 
now repeating that study with our extracellular UW 
formulation. 
Endothelial damage has been implicated in the 
development of atherosclerosis. Cartier and associ- 
ates 3s found that regenerating denuded endothe- 
lium has abnormal function up to 8 weeks after 
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injury, which predisposes the vessel to vasospasm 
and thrombosis. 
The concentration of potassium of 25 mEq/L was 
chosen as a compromise between the prevention of 
endothelial damage and the need to ensure rapid 
cardiac arrest. It was noted that the hearts that 
received low-potassium UW solution arrested rap- 
idly but generally not as quickly as those that 
received the high-potassium solution. Rapid arrest 
is desirable to ensure the presence of large ATP 
stores during cold storage. 
Future studies may evaluate solutions with potas- 
sium concentrations lower than 25 mEq/L, because 
some endothelial dysfunction has been observed 
with potassium levels close to 25 mEq/L. 13' 34 We 
recently demonstrated that multidose UW solution 
is superior to multidose blood cardioplegia for in- 
traoperative myocardial protection. 36 Multidose 
extracellular UW solution may provide similar pro- 
tection without inducing endothelial dysfunction. 
Low-potassium UW solution may also have benefits 
in liver transplantation, eliminating the need for 
flushout of the liver before reperfusion. 29Extracel- 
lular UW solution provides equivalent myocardial 
protection and appears to decrease the likelihood of 
endothelial injury. Future studies will specifically 
compare endothelial function with the two solu- 
tions. A randomized clinical trial is presently 
planned. 
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